Kaposi Sarcoma Differential Diagnoses

  • Author: Lewis J Rose, MD; Chief Editor: Jules E Harris, MD   more...
 
Updated: Aug 5, 2011
 
 

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Lewis J Rose, MD  Clinical Associate Professor of Medical Oncology, Division of Regional Cancer Care, Kimmel Cancer Center, Thomas Jefferson University Hospital; Consulting Staff, LRCRZ Associates

Lewis J Rose, MD is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Hematology, Pennsylvania Medical Society, Phi Beta Kappa, and Philadelphia County Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Ari D Fishman, MD  Fellow, Department of Medical Oncology, Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine

Ari D Fishman, MD is a member of the following medical societies: American College of Physicians, American Medical Association, and American Society of Hematology

Disclosure: Nothing to disclose.

Joseph A Sparano, MD  Professor of Medicine, Albert Einstein College of Medicine/Cancer Center; Program Director, Director of Breast Medical Oncology, Department of Internal Medicine, Division of Oncology, Montefiore Medical Center

Joseph A Sparano, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, and American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael Perry, MD, MS, MACP  Nellie B Smith Chair of Oncology Emeritus, Professor, Department of Internal Medicine, Division of Hematology and Oncology, Ellis Fischel Cancer Center, University of Missouri-Columbia School of Medicine

Michael Perry, MD, MS, MACP is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, International Association for the Study of Lung Cancer, and Missouri State Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rajalaxmi McKenna, MD, FACP  Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD  Clinical Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine; Consulting Staff, Arizona Cancer Center

Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research

Disclosure: GlobeImmune Salary Consulting

References

  1. DeVita V. AIDS-related malignancies. In: DeVita V, Vincent T Jr, eds. Cancer: Principles and Practice of Clinical Oncology. Vol 8. 5th ed. Philadelphia, Pa: Lippincott, Williams, & Wilkins; 2008:2404-2407.

  2. Renwick N, Halaby T, Weverling GJ, et al. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS. Dec 24 1998;12(18):2481-8. [Medline].

  3. Jacobson LP, Jenkins FJ, Springer G, et al. Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis. Jun 2000;181(6):1940-9. [Medline].

  4. Escalon MP and Hagemeister FB. AIDS-Related Malignancies. In: Kantarjian HM, Wolff Ra, and Koller CA. MD Anderson Manual of Medical Oncology. McGraw-Hill; 2006:903-910. [Full Text].

  5. Nawar E, Mbulaiteye SM, Gallant JE, Wohl DA, Ardini M, Hendershot T, et al. Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS. Int J Cancer. Jun 10 2005;115(2):296-300. [Medline].

  6. Penn I. Cancer in the immunosuppressed organ recipient. Transplant Proc. Apr 1991;23(2):1771-2. [Medline].

  7. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am. Apr 1993;7(2):431-45. [Medline].

  8. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. Apr 6 2000;342(14):1027-38. [Medline].

  9. Franceschi S, Geddes M. Epidemiology of classic Kaposi's sarcoma, with special reference to mediterranean population. Tumori. Sep-Oct 1995;81(5):308-14. [Medline].

  10. Sarid R, Olsen SJ, Moore PS. Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res. 1999;52:139-232. [Medline].

  11. Touloumi G, Hatzakis A, Potouridou I, et al. The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. Int J Cancer. Sep 9 1999;82(6):817-21. [Medline].

  12. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. Mar 31 2005;352(13):1317-23. [Medline].

  13. Gutiérrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant. May 2007;22 Suppl 1:i11-6. [Medline].

  14. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. Feb 2006;17(2):581-9. [Medline].

  15. Kaloterakis A, Papasteriades C, Filiotou A, et al. HLA in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece. Tissue Antigens. Feb 1995;45(2):117-9. [Medline].

  16. Calabrò ML, Sheldon J, Favero A, et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J Hum Virol. Mar-Apr 1998;1(3):207-13. [Medline].

  17. Iscovich J, Boffetta P, Winkelmann R, Brennan P. Classic Kaposi's sarcoma as a second primary neoplasm. Int J Cancer. Jan 18 1999;80(2):178-82. [Medline].

  18. Fiorelli V, Gendelman R, Sirianni MC, et al. gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection?. Blood. Feb 1 1998;91(3):956-67. [Medline].

  19. Monini P, Colombini S, Sturzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood. Jun 15 1999;93(12):4044-58. [Medline].

  20. Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. J Natl Cancer Inst. Nov 20 2002;94(22):1712-8. [Medline].

  21. de-Thé G, Bestetti G, van Beveren M, et al. Prevalence of human herpesvirus 8 infection before the acquired immunodeficiency disease syndrome-related epidemic of Kaposi's sarcoma in East Africa. J Natl Cancer Inst. Nov 3 1999;91(21):1888-9. [Medline].

  22. Parkin DM FJ, Hamdi-Cherif M, Sitas F, et al. Kaposi's Sarcoma. In: Cancer in Africa: Epidemiology and Preventiion. 153. Lyon, France: International Agency for Research on Cancer: IARC Scientific Publiciations; 2003:286-294.

  23. Ziegler J, Newton R, Bourboulia D, et al. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer. Jan 10 2003;103(2):233-40. [Medline].

  24. Osman M, Kubo T, Gill J, Neipel F, Becker M, Smith G, et al. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol. Jul 1999;73(7):6136-40. [Medline]. [Full Text].

  25. Sirianni MC, Vincenzi L, Topino S, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol. Oct 2002;32(10):2711-20. [Medline].

  26. Friedman-Kien AE, Saltzman BR, Cao YZ, et al. Kaposi's sarcoma in HIV-negative homosexual men. Lancet. Jan 20 1990;335(8682):168-9. [Medline].

  27. Uccini S, Ruco LP, Monardo F, Stoppacciaro A, et al. Co-expression of endothelial cell and macrophage antigens in Kaposi's sarcoma cells. J Pathol. May 1994;173(1):23-31. [Medline].

  28. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet. Sep 28 1996;348(9031):858-61. [Medline].

  29. Spira TJ, Lam L, Dollard SC, et al. Comparison of serologic assays and PCR for diagnosis of human herpes virus 8 infection. J Clin Microbiol. Jun 2000;38(6):2174-80. [Medline]. [Full Text].

  30. Nascimento, MC, Sumita, LM, Souza, VU, et al. Seroprevalence of Kaposi Sarcoma –associated herpes virus and other serologic markers in the Brazilian Amazon. Emerg Infect Dis. 2009;15:664-667.

  31. Wang X, He B, Zhang Z, et al. Human herpesvirus-8 in northwestern China: epidemiology and characterization among blood donors. Virol J. Mar 17 2010;7:62. [Medline]. [Full Text].

  32. Duprez R, Lacoste V, Brière J, Couppié P, Frances C, Sainte-Marie D, et al. Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J Natl Cancer Inst. Jul 18 2007;99(14):1086-94. [Medline].

  33. Montaner S, Sodhi A, Ramsdell AK, et al. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res. Jan 1 2006;66(1):168-74. [Medline].

  34. Grisotto MG, Garin A, Martin AP, Jensen KK, Chan P, Sealfon SC, et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J Clin Invest. May 2006;116(5):1264-73. [Medline]. [Full Text].

  35. Paulose-Murphy M, Ha NK, Xiang C, Chen Y, Gillim L, Yarchoan R, et al. Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol. May 2001;75(10):4843-53. [Medline]. [Full Text].

  36. Biggar, RJ, Chatuvedi, AK, Goedert, JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:969-972.

  37. Brown EE, Whitby D, Vitale F, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer. Nov 1 2006;107(9):2282-90. [Medline].

  38. Stratigos AJ, Malanos D, Touloumi G, et al. Association of clinical progression in classic Kaposi's sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers. Arch Dermatol. Nov 2005;141(11):1421-6. [Medline].

  39. Kimball LE, Casper C, Koelle DM, Morrow R, Corey L, Vieira J. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis. Jun 1 2004;189(11):2016-22. [Medline].

  40. Campbell TB, Borok M, Ndemera B, et al. Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe. Clin Infect Dis. Jun 1 2009;48(11):1601-8. [Medline]. [Full Text].

  41. Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. Sep 28 2006;355(13):1331-8. [Medline].

  42. Frances C, Marcelin AG, Legendre Ch, et al. The impact of preexisting or acquired Kaposi sarcoma herpes virus infection in kidney transplant recipients on morbidity and survival. Am J Transplant. Nov 2009;9(11):2580-6. [Medline].

  43. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. Dec 16 1994;266(5192):1865-9. [Medline].

  44. SEER Cancer Statistics Review authored by Reis LAG, Eisner MP, Kosary, CL et al [database online]. Bethesda, MD: National Cancer Institute; 2003.

  45. Scadden D. Acquired Immunodeficiency Syndrome. In: Holland JF, Frei E. Cancer Medicine. 6. Hamilton, London: BC Decker Inc; 2003:2259-2275.

  46. Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. Aug 21 2002;94(16):1204-10. [Medline].

  47. Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?. Lancet. Jan 20 1990;335(8682):123-8. [Medline].

  48. Cote TR, Howe HL, Anderson SP, et al. A systemic consideration of the neoplastic spectrum of AIDS: registry linkage in Illinois. AIDS. 1991;5(1):49-53.

  49. [Best Evidence] Stebbing J, Sanitt A, Nelson M, et al. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet. May 6 2006;367(9521):1495-502. [Medline].

  50. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med. Sep 27 2007;357(13):1352-3. [Medline].

  51. Lee FC, Mitsuyasu RT. Chemotherapy of AIDS--related Kaposi's sarcoma. Hematol Oncol Clin North Am. Oct 1996;10(5):1051-68. [Medline].

  52. Hussein MA, Remzi B, DiFabrizio L, et al. Evaluation of Sequential Thallium and Gallium Scans of the Chest in AIDs Patients. The Journal of Nuclear Medicine. October, 1996;37, 10:1662-1667.

  53. About the 3 by 5 Initiative. World Health Organization. WHO website. Available at http://www.who.int/3by5/about/initiative/en/endex.html. Accessed September 6, 2004.

  54. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer. Jul 2001;37(10):1288-95. [Medline].

  55. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. Jul 1 2002;95(1):147-54. [Medline].

  56. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. Feb 1 2004;22(3):399-402. [Medline].

  57. Chachoua A, Krigel R, Lafleur F, et al. Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma. J Clin Oncol. Jun 1989;7(6):774-80. [Medline].

  58. Cattelan AM, Calabro ML, De Rossi A, et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol. Sep 2005;27(3):779-85. [Medline].

  59. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol. Aug 1 2005;23(22):5224-8. [Medline].

  60. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. Mar 2002;8(3):225-32. [Medline].

  61. Cooper A. Treating HIV-infected children: the surgeon's role. Bull Am Coll Surg. Jun 1991;76(6):13-7, 43. [Medline].

  62. Nobler MP, Leddy ME, Huh SH. The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome. J Clin Oncol. Jan 1987;5(1):107-12. [Medline].

  63. Mosam A, Shaik F, Uldrick T, Esterhuizen T, Friedlnad G, Scadden D, et al. The KAART Trial: A randomized controlled trial of HAART compared to the combination of HAART and chemotherapy in treatment naïve patients with HIV-associated Kaposi's Sarcoma (HIV-KS) in KwaZulu-Natal (KZN) South Africa NCT 00380770 in: 17th Conference on Retorviruses and Opportunistic Infections, San Francisco, CA . 2010.

  64. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol. Apr 1986;4(4):544-51. [Medline].

  65. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med. May 1984;100(5):671-6. [Medline].

  66. Krown SE, Gold JW, Niedzwiecki D, et al. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. Jun 1 1990;112(11):812-21. [Medline].

  67. Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood. Jun 15 2006;107(12):4650-7. [Medline]. [Full Text].

  68. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. Jul 1998;16(7):2445-51. [Medline].

  69. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. Feb 1998;16(2):683-91. [Medline].

  70. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. Aug 1996;14(8):2353-64. [Medline].

  71. Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. Jul 1 1995;346(8966):26-8. [Medline].

  72. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. Jun 1999;17(6):1876-83. [Medline].

  73. Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, et al. Pegylated liposomal doxorubicin plus high active antiretroviral therapy verusus Highy active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18:410-417.

  74. Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer Lett. Jun 28 2011;305(2):150-62. [Medline]. [Full Text].

  75. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. Feb 10 2005;23(5):982-9. [Medline].

  76. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. Jan 1 2002;20(1):153-9. [Medline].

  77. Infectious Agents, Immunologic Factors, Hereditary Neoplastic Syndromes, Soft Tissue Sarcoma. In: Schottenfeld D and Fraumen J eds. Cancer. Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:522, 523, 552, 553, 561, 562, 960-962, 968.

  78. Centers for disease control. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR. 1999;48:SS2:1-22.

  79. de Sanjose S, Mbisa G, Perez-Alvarez S, et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis. May 15 2009;199(10):1449-56. [Medline].

  80. Dezube BJ. Acquired immunodeficiency syndrome-related Kaposi's sarcoma: clinical features, staging, and treatment. Semin Oncol. Aug 2000;27(4):424-30. [Medline].

  81. Dezube BJ. Clinical presentation and natural history of AIDS--related Kaposi's sarcoma. Hematol Oncol Clin North Am. Oct 1996;10(5):1023-9. [Medline].

  82. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. Feb 2007;8(2):167-76. [Medline].

  83. Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. Aug 1 2002;20(15):3236-41. [Medline].

  84. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. Aug 1996;2(8):925-8. [Medline].

  85. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. Jun 1999;17(6):1876-83. [Medline].

  86. Iscovich J, Boffetta P, Franceschi S, et al. Classic kaposi sarcoma: epidemiology and risk factors. Cancer. Feb 1 2000;88(3):500-17. [Medline].

  87. Krown SE, Lee JY, Dittmer DP. More on HIV-associated Kaposi's sarcoma. N Engl J Med. Jan 31 2008;358(5):535-6; author reply 536. [Medline]. [Full Text].

  88. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. Sep 1989;7(9):1201-7. [Medline].

  89. Mbisa GL, Miley W, Gamache CJ, et al. Detection of antibodies to Kaposi's sarcoma-associated herpes virus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods. Apr 30 2010;356(1-2):39-46. [Medline]. [Full Text].

  90. AIDS-Related Malignancies-Kaposi's Sarcoma. In: Kantarjian HM, Wolff RA, and Koller CA. MD Anderson Manual of Medical Oncology. McGraw Hill; 2006:903-910/34.

  91. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. Oct 26 1996;348(9035):1133-8. [Medline].

  92. Stebbing J, Gazzard B, Newsom-Davis T, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int J Cancer. Jan 20 2004;108(3):473-4. [Medline].

  93. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. Feb 2000;18(4):716-23. [Medline].

  94. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. Feb 2000;18(4):716-23. [Medline].

  95. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature. Oct 13 1988;335(6191):606-11. [Medline].

  96. Von Roenn J. Kaposi's sarcoma evaluation and treatment. In: American Society of Clinical Oncology (ASCO) Educational book. 1998:76-85.

  97. Yarchoan R, Broder S. Preliminary results on the use of dideoxynuclosides in the therapy of AIDS. In: Chanock, RM, Lerner Ra, Brown F, Ginsberg H. Vaccines 87: modern approaches to new vaccines: prevention of AIKDs and other viral, bacterial, and parasitic disease. Cold Spring Harbor, NY: Colc Spring Harbor Press; 1987.

 
Previous
Next
 
Endoscopic view of a Kaposi sarcoma lesion situated in the gastric antrum.
Epidemic Kaposi sarcoma (KS). Large violaceous truncal nodules with typical linear and symmetric distribution pattern.
Kaposi sarcoma (KS), facial. Confluent, violaceous nodules involving the chest wall; extensive facial involvement with accompanied edema.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.